Citation Impact
Citing Papers
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications
2010
A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
2012
A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2012
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
2011
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
2012 Standout
A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
2014
Vismodegib
2012
Engineering precision nanoparticles for drug delivery
2020 Standout
Parkinson disease
2017 Standout
The mechanisms of Hedgehog signalling and its roles in development and disease
2013 Standout
Quantitative structure–pharmacokinetic/pharmacodynamic relationships
2006
Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?
2009
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
Genetic basis for individual variations in pain perception and the development of a chronic pain condition
2004 Standout
Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
2004 Standout
Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys
2000
Modelling hepatitis C therapy—predicting effects of treatment
2015
Catechol-O-Methyltransferase Inhibition Improves Set-Shifting Performance and Elevates Stimulated Dopamine Release in the Rat Prefrontal Cortex
2004
The Hedgehog's tale: developing strategies for targeting cancer
2011
xCell: digitally portraying the tissue cellular heterogeneity landscape
2017 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Drug-Induced Hepatotoxicity
2003 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Pharmacokinetic and tolerability profile of twice‐daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers
2003
COVID-19: A promising cure for the global panic
2020 Standout
Nuclear receptor PXR, transcriptional circuits and metabolic relevance
2011
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
2015
Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity
2002
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Cancer stem cells revisited
2017 Standout
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
2010
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Gut microbiome and health: mechanistic insights
2022 Standout
Replication Vesicles are Load- and Choke-Points in the Hepatitis C Virus Lifecycle
2013
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
2007 Standout
Interferon-based therapy of hepatitis C
2007
Parkinson's disease
2015 Standout
Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
2008
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
2015
Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer
2012
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
2003
Evidence‐Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
2008
Tolcapone and Hepatotoxic Effects
2000
Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
2012 Standout
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study
2016
Expert opinion on the treatment of patients with chronic hepatitis C
2008
The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity
2017 StandoutNobel
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Acetaminophen‐induced acute liver failure
2005 Standout
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
2004 Standout
The Physiology of Glucagon-like Peptide 1
2007 Standout
Safety evaluation of superabsorbent baby diapers
2008
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Effects of entacapone and tolcapone on mitochondrial membrane potential
2002
Tackling the cancer stem cells — what challenges do they pose?
2014
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
2010 Standout
Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
2011
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson???s Disease
2000
Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond
2006
Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
2017
A catechol- O -methyltransferase that is essential for auditory function in mice and humans
2008 StandoutNobel
Synthesis and swelling behaviors of sodium carboxymethyl cellulose-g-poly(AA-co-AM-co-AMPS)/MMT superabsorbent hydrogel
2010 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
The Organocatalytic Approach to Enantiopure 2H‐ and 3H‐Pyrroles: Inhibitors of the Hedgehog Signaling Pathway
2016 StandoutNobel
Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 2: Exposure–response analyses for efficacy and safety variables
2014
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Gut microbiota are related to Parkinson's disease and clinical phenotype
2014 Standout
Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates
2014
ProTox-II: a webserver for the prediction of toxicity of chemicals
2018 Standout
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
2013
Combination therapy in combating cancer
2017 Standout
Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors
1999
Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
2008
A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes
2014 StandoutNobel
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1
2007
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
2001 Standout
Towards a small animal model for hepatitis C
2009 StandoutNobel
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States
2011
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon‐alpha therapy via mathematical modeling
2014
Industry sponsorship and research outcome
2017 Standout
Works of Karin Jorga being referenced
Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
2011
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly*
1997
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans*
1995
The Effect of COMT Inhibition by Tolcapone on Tolerability and Pharmacokinetics of Different Levodopa/Benserazide Formulations
1997
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirin
2006
Pharmacokinetics of ribavirin in patients with hepatitis C virus
2006
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
1998
Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase
1999
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
2006
Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites*
1998
The effect of tolcapone on the pharmacokinetics of benserazide
1999
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration
2001
Effect of Tolcapone on Plasma Levodopa Concentrations after Coadministration with Levodopa/Carbidopa to Healthy Volunteers
1997
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
2010
Multiple-dose clinical pharmacology of the catechol- O -methyl-transferase inhibitor tolcapone in elderly subjects
1996
The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients
2001
Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers
2000
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy
1998
Clinical, Pharmacokinetic, and Pharmacodynamic Effects of Tolcapone Withdrawal in Levodopa-Treated Patients with Parkinsonism
2000
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone
1998
Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa.
1995
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
2009
18F‐dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
2001